Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
Viral Structure00:56

Viral Structure

Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adaptive Proton Therapy for Pediatric Parameningeal Rhabdomyosarcoma: On-Treatment Anatomic Changes and Timing to Replanning.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development.

Blood advances·2020
Same author

Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Pilot randomized, non-inferiority, cross-over trial of once-weekly vs. three times-weekly recombinant factor VIII prophylaxis in adults with severe haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES.

Alimentary pharmacology & therapeutics·2016
Same journal

Prophylactic Factor Replacement Versus on-Demand Factor Replacement Following Primary Total Knee Arthroplasty in Patients With Hemophilia: A Retrospective Study With an Average 10-Year Follow-up.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Accuracy of Factor VIII Assays for Measuring Damoctocog Alfa Pegol: A Comparative Analysis.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Real-World Assessment of rVIII-SingleChain for Prophylactic Treatment in People With Severe Hemophilia A in High-Resource Settings.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Platelet Hyperreactivity May Contribute to Thrombotic Complications in Afibrinogenemia: A Case-Based Observation.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Predictors and Clinical Impact of Time to Diagnosis in Acquired Haemophilia A: An 11-Year Retrospective Cohort Study.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Clinical Outcomes of Efanesoctocog Alfa Prophylaxis in Children With Severe Haemophilia A: Interim Data From XTEND-ed.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2026

Protocols for Investigating the Host-tissue Distribution, Transmission-mode, and Effect on the Host Fitness of a Densovirus in the Cotton Bollworm
11:12

Protocols for Investigating the Host-tissue Distribution, Transmission-mode, and Effect on the Host Fitness of a Densovirus in the Cotton Bollworm

Published on: April 12, 2017

Viral pathogens.

M V Ragni1, K E Sherman, J A Jordan

  • 1Department of Medicine, Division Hematology/Oncology, University of Pittsburgh Medical Center and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA 15213-4306, USA. ragni@pitt.edu

Haemophilia : the Official Journal of the World Federation of Hemophilia
|July 2, 2010
PubMed
Summary
This summary is machine-generated.

Transfusion-transmitted viral pathogens like HIV and hepatitis C remain a concern for individuals with haemophilia, despite advancements. New screening methods are being considered for parvovirus B19 to improve blood safety.

More Related Videos

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods
10:40

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods

Published on: December 21, 2019

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Related Experiment Videos

Last Updated: Jun 11, 2026

Protocols for Investigating the Host-tissue Distribution, Transmission-mode, and Effect on the Host Fitness of a Densovirus in the Cotton Bollworm
11:12

Protocols for Investigating the Host-tissue Distribution, Transmission-mode, and Effect on the Host Fitness of a Densovirus in the Cotton Bollworm

Published on: April 12, 2017

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods
10:40

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods

Published on: December 21, 2019

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Area of Science:

  • Hematology
  • Infectious Diseases
  • Hepatology

Background:

  • Individuals with haemophilia are at increased risk for transfusion-transmitted viral infections.
  • Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are significant co-morbidities.
  • Human parvovirus B19 poses a unique challenge due to its resistance to standard inactivation methods.

Purpose of the Study:

  • To provide an update on three clinically significant transfusion-transmitted viral pathogens affecting individuals with haemophilia.
  • To discuss the impact and management of HIV, hepatitis C, and parvovirus B19 in this population.
  • To highlight advancements in blood product safety and ongoing challenges.

Main Methods:

  • Review of current literature on viral pathogens in haemophilia.
  • Discussion of clinical manifestations, treatment outcomes, and management strategies.
  • Analysis of existing and emerging technologies for viral screening and inactivation.

Main Results:

  • Hepatitis C is the leading cause of chronic liver disease in haemophilia patients, with current treatments effective in 70% of cases.
  • HIV is managed as a chronic infection with highly active antiretroviral therapy (HAART), which also benefits HCV co-infection.
  • Parvovirus B19 infection can cause anemia or aplastic crisis; nucleic acid testing (NAT) is under consideration for blood screening.

Conclusions:

  • While viral inactivation and recombinant technologies have improved blood safety, ongoing vigilance is necessary.
  • Effective management of HIV and HCV contributes to improved lifespan for individuals with haemophilia.
  • Enhanced screening, such as NAT for parvovirus B19, is crucial for further reducing transfusion-transmitted infections.